Bionik Laboratories

Bionik Laboratories FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Bionik Laboratories (BNKL) as of Nov 2, 2026 is 68.66 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 39.97 % — a change of 71.79% (higher).

FCF Conversion

68.66 %

YoY

71.79%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Bionik Laboratories is 2023 68.66 % . FCF Conversion Rate (FCF/EBITDA) of Bionik Laboratories was 2022 39.97 % . It decreases by 71.79% higher compared to the previous year.

The Bionik Laboratories FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2016
-462.36 USD
Jan 1, 2017
181.96 USD
Jan 1, 2018
52.50 USD
Jan 1, 2019
88.42 USD
Jan 1, 2020
36.99 USD
Jan 1, 2021
33.95 USD
Jan 1, 2022
39.97 USD
Jan 1, 2023
68.66 USD
The Bionik Laboratories FCF Conversion history
YEARFCF ConversionYoY
68.66 %+71.79%
39.97 %+17.73%
33.95 %-8.22%
36.99 %-58.17%
88.42 %+68.43%
52.50 %-71.15%
181.96 %-139.36%
-462.36 %-1,125.47%
45.09 %-59.54%
111.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bionik Laboratories Stock analysis

What does Bionik Laboratories do? Bionik Laboratories Corp. generates revenue through its portfolio of rehabilitation products designed for neurological and mobility-impaired patients. The company offers InMotion ARM, InMotion ARM/HAND, and InMotion Robots as fully developed clinical solutions, with InMotion CONNECT serving as a complementary platform. InMotion Home is in development as an at-home upper extremity therapy product. These products target healthcare providers and rehabilitation centers seeking advanced robotic therapies for stroke and mobility disorders. The company's focus on AI-driven rehabilitation solutions positions it to serve the growing market for smart, patient-centric mobility recovery systems. The business model relies on selling robotic therapy systems and software platforms to clinical facilities and home care settings. InMotion ARM and InMotion ARM/HAND are deployed in professional rehabilitation environments, while InMotion Home aims to expand access to therapy beyond clinical walls. InMotion CONNECT supports data-driven treatment planning and progress tracking, enhancing the value proposition for healthcare institutions. The company monetizes through product sales and potentially service contracts for its AI-enhanced rehabilitation systems. Bionik Laboratories Corp. targets healthcare providers specializing in neurological rehabilitation, including hospitals and outpatient clinics. Its products address upper and lower extremity rehabilitation needs, with a primary focus on stroke recovery. The company's development pipeline includes three market-ready products and three in various stages of development, ensuring a steady stream of revenue opportunities as products progress from development to commercialization. Bionik Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bionik Laboratories stock

FCF Conversion Rate (FCF/EBITDA) of Bionik Laboratories is 68.66 % in 2023.

FCF Conversion Rate (FCF/EBITDA) of Bionik Laboratories changed from 39.97 % to 68.66 %, representing a 71.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Bionik Laboratories since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Bionik Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Bionik Laboratories

All Key Metrics — Bionik Laboratories